Eric Vachon on the Effect of Complexity on Adherence with Kinase Inhibitors
Eric Vachon, BSN, PhD candidate, discusses the importance of taking all variables of complexity into account when considering adherence to kinase inhibitors.
Eric Vachon, BSN, PhD candidate, Michigan State University, discusses the many variables of complexity that can effect adherence to kinase inhibitors.
The regimen for kinase inhibitors is the most complex. Many current studies focus only on the issue of continuous versus cycling. However, there are other considerations that Vachon is studying in his own research.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
